1. Home
  2. GDL vs CSBR Comparison

GDL vs CSBR Comparison

Compare GDL & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

HOLD

Current Price

$8.34

Market Cap

90.7M

Sector

Finance

ML Signal

HOLD

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

N/A

Current Price

$5.73

Market Cap

82.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GDL
CSBR
Founded
2006
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.7M
82.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
GDL
CSBR
Price
$8.34
$5.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.1K
8.2K
Earning Date
01-01-0001
03-12-2026
Dividend Yield
6.02%
N/A
EPS Growth
N/A
161.11
EPS
N/A
N/A
Revenue
N/A
$2,900,000.00
Revenue This Year
N/A
$4.84
Revenue Next Year
N/A
$11.51
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.81
$5.50
52 Week High
$8.67
$9.63

Technical Indicators

Market Signals
Indicator
GDL
CSBR
Relative Strength Index (RSI) 55.50 55.47
Support Level $8.39 $6.11
Resistance Level $8.47 $6.29
Average True Range (ATR) 0.10 0.25
MACD 0.01 0.05
Stochastic Oscillator 67.12 84.68

Price Performance

Historical Comparison
GDL
CSBR

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: